Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial
Open Access
- 13 September 2017
- journal article
- research article
- Published by Elsevier BV in The Lancet Diabetes & Endocrinology
- Vol. 5 (11), 877-886
- https://doi.org/10.1016/s2213-8587(17)30309-1
Abstract
No abstract availableKeywords
Funding Information
- Bayer
This publication has 23 references indexed in Scilit:
- Effects of 24-week treatment with acarbose on glucagon-like peptide 1 in newly diagnosed type 2 diabetic patients: a preliminary reportCardiovascular Diabetology, 2013
- Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studiesThe Lancet, 2010
- Effect of Nateglinide on the Incidence of Diabetes and Cardiovascular EventsThe New England Journal of Medicine, 2010
- Determining the most appropriate components for a composite clinical trial outcomeAmerican Heart Journal, 2008
- Glucagon-Like Peptide-1 Infusion Improves Left Ventricular Ejection Fraction and Functional Status in Patients With Chronic Heart FailureJournal of Cardiac Failure, 2006
- Modified Glomerular Filtration Rate Estimating Equation for Chinese Patients with Chronic Kidney DiseaseJournal of the American Society of Nephrology, 2006
- The relationship between coronary artery disease and abnormal glucose regulation in China: the China Heart SurveyEuropean Heart Journal, 2006
- Acarbose Slows Progression of Intima-Media Thickness of the Carotid Arteries in Subjects With Impaired Glucose ToleranceStroke, 2004
- A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44)Diabetes Care, 1999
- The Natural History of Impaired Glucose Tolerance in the Pima IndiansThe New England Journal of Medicine, 1988